Akari Therapeutics (AKTX)
0.92
-0.02 (-1.81%)
At close: Mar 04, 2025, 9:45 AM
Akari Therapeutics Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 4K | 3.71K | 4.13K | 8.91K | 19.2K | 35.85K | 42.4K | 39.77K | 10.16K | n/a | n/a | n/a | n/a | n/a |
| Gross Profit | -4K | -3.71K | -4.13K | -8.91K | -19.2K | -35.85K | -42.4K | -39.77K | -10.16K | n/a | n/a | n/a | n/a | n/a |
| Operating Income | -16.81M | -23.09M | -17.21M | -17.98M | -24.87M | -19.99M | -34.96M | -27.25M | -30.58M | -10.18M | -3.61M | -3.67M | -2.25M | -792K |
| Interest Income | 82K | 45.94K | 10.6K | 13K | 5K | 222.26K | 175.39K | 143.19K | 20.7K | n/a | n/a | 440K | n/a | 122K |
| Pretax Income | -10.01M | -17.75M | -17.42M | -20.45M | -24.75M | -23.5M | -32.57M | -18.14M | -45.32M | -9.65M | -3.62M | -1.44M | -2.12M | -675K |
| Net Income | -10.01M | -6.97M | -17.61M | -17.6M | -21.76M | -19.95M | -27.92M | -18.14M | -45.32M | -9.65M | -3.62M | -1.44M | -2.12M | -675K |
| Selling & General & Admin | 11.36M | 13.53M | 8.08M | 7.91M | 8.22M | 10.9M | 11.67M | 9.94M | 5.5M | 3.76M | 2.33M | 734K | 1.41M | 545K |
| Research & Development | 12.13M | 9.56M | 9.13M | 12.19M | 16.65M | 15.59M | 23.29M | 17.31M | 5.8M | 6.42M | 1.28M | 1.02M | 841K | 247K |
| Other Expenses | -6.68M | 802.79K | -27.48K | -22.01K | 19K | -2.68M | -13.39K | -43.97K | -44.22K | n/a | n/a | n/a | n/a | n/a |
| Operating Expenses | 16.81M | 23.89M | 17.21M | 20.1M | 24.89M | 23.8M | 34.96M | 27.25M | 11.3M | 10.18M | 3.61M | 1.75M | 2.25M | 792K |
| Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 9.15M | 3.05M | n/a | 202K | 1.04M | n/a | 5K |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 16.81M | 23.09M | 17.21M | 20.1M | 24.89M | 23.8M | 34.96M | 27.25M | 11.3M | 10.18M | 3.61M | 1.75M | 2.25M | 792K |
| Income Tax | n/a | -10.78M | 182.62K | -2.86M | -2.99M | -3.55M | -4.65M | -43.97K | 3.01M | n/a | 202K | 1.92M | 9K | n/a |
| Shares Outstanding (Basic) | 4.89M | 3.12M | 2.15M | 1.58M | 915.5K | 15.81M | 12.47M | 11.78M | 8.52M | 855.16K | 210.75K | 124.59K | 133.7K | 133.7K |
| Shares Outstanding (Diluted) | 4.89M | 3.12M | 2.15M | 1.58M | 915.5K | 15.81M | 12.47M | 11.78M | 8.52M | 855.16K | 210.75K | 124.59K | 133.7K | 133.7K |
| EPS (Basic) | -2.04 | -2.23 | -8.2 | -11.14 | -23.77 | -1.26 | -2.24 | -1.54 | -5.32 | -11.28 | -17.18 | -11.52 | -15.85 | -5.05 |
| EPS (Diluted) | -2.04 | -2.23 | -8.2 | -11.14 | -23.77 | -1.26 | -2.24 | -1.54 | -5.32 | -11.28 | -17.18 | -11.52 | -15.85 | -5.05 |
| EBITDA | -16.8M | -23.08M | -17.21M | -20.44M | -24.73M | -16.43M | -35.36M | -27.25M | -19.28M | -10.19M | -3.42M | -3.36M | -2.12M | -675.88K |
| Depreciation & Amortization | 4K | 3.71K | 4.13K | 8.91K | 19.2K | 35.85K | 42.4K | 39.77K | 10.16K | 8K | 2K | 2K | -137K | n/a |